Top

Published in:

01-06-2018 | Case Report

EGIST: a Rare Tumor

Authors: Diogo Sousa, Miguel Allen, André Mateus, Ana Cruz, Diogo Marinho, Andreia Ferreira, Pierpaolo Cusati, José Augusto Martins

Published in: Journal of Gastrointestinal Cancer | Issue 2/2018

Excerpt

Gastrointestinal stromal tumors (GISTs) are rare neoplasms that represent only 0.1–3 % of all gastrointestinal malignancies. However, they are the most common mesenchymal gastrointestinal neoplasm, accounting for 80 % of all cases [1]. Its incidence has increased considerably in the past years due to growing investigation and knowledge on the features of this disease; in fact, many of the previously reported mesenchymal gastrointestinal tumors are now thought to have been misdiagnosed. …

Raut C, Pawlik T. Gastrointestinal stromal tumors. In: Current surgical therapy. 11th ed: Elsevier-Saunders; 2014. p. 96–103.

Monabati A, Safavi M, Solhjoo F. Extragastrointestinal stromal tumor presenting as omental cyst. J Gastrointest Surg. 2016. doi:10.1007/s11605-016-3098-y.PubMed

Trombatore C, Palmucci S, Angelico G, Vasquez E, Petrillo G, Puleo S, Cataldo A. Extragastrointestinal stromal tumor of lesser omentum: a challenging radiological and histological diagnosis. Clin Imaging. 2015;33:1123–7.CrossRef

Feldman M. Gastrointestinal stromal tumors (GISTs). In: Sleisenger and Fordtran’s gastrointestinal and liver disease. 10th ed: Elsevier-Saunders; 2016. p. 487–500.

Rubin B. GIST and EGIST. In: Enzinger and Weiss’s soft tissue tumors. 6th ed: Elsevier-Saunders; 2014. p. 569–90.

Rutkowski P, Gronchi A, Hohenberger P, et al. Neoadjuvant imatinib in local advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013;20:2937–43.CrossRefPubMed

NCCN Clinical Practice Guidelines in Oncology. Soft tissue sarcoma. V 2.2012. 2012.

Zhong Y, Deng M, Liu B, et al. Primary gastrointestinal stromal tumors: current advances in diagnostic biomarkers, prognostic factors and management of its duodenal location. Intractable Rare Dis Res. 2013;2(1):11–7.PubMedPubMedCentral

Title: EGIST: a Rare Tumor
Authors: Diogo Sousa
Miguel Allen
André Mateus
Ana Cruz
Diogo Marinho
Andreia Ferreira
Pierpaolo Cusati
José Augusto Martins
Publication date: 01-06-2018
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 2/2018
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-016-9856-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

EGIST: a Rare Tumor

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2018

Comparison of Clinical Outcomes Between Laparoscopic-Assisted and Minilaparotomy Approaches for Colon Cancer

Simple Clinical Score to Predict 24-Week Survival Times in Patients with Inoperable Malignant Distal Biliary Obstruction as a Tool for Selecting Palliative Metallic or Plastic Stents

Long-Term Survival with Chemoradiation Alone in Locally Advanced Unresectable Gallbladder Cancer: First Case Report of a New Paradigm

Author Correction: Opium Consumption and the Incidence of Cancer: Does Opium Account as an Emerging Risk Factor for Gastrointestinal Cancer?

Small Bowel Obstruction Secondary to Ileal Mucosa-Associated Lymphoid Tissue Lymphoma

Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page